Similar companies
Did Collegium Pharmaceutical Beat Earnings?
Collegium Pharmaceutical (COLL) reported Q2 '26 revenue of $200M, up 6.3% year-over-year, with reported EPS of $1.57. That topped the $1.48 analyst estimate by 6.1% — an earnings beat.
AltIndex tracks earnings alongside 25+ alternative data signals that can move ahead of the report — Collegium Pharmaceutical’s job postings, web traffic, and employee business outlook. See the full COLL stock analysis or the earnings calendar for upcoming reports.
COLL Earnings Surprise History (EPS vs. Estimate)
| Quarter | Estimated EPS | Reported EPS | Surprise |
|---|---|---|---|
| Q2 '26 | $1.48 | $1.57 | Beat +6.1% |
| Q1 '26 | $1.52 | $1.76 | Beat +15.8% |
| Q4 '25 | $2.01 | $1.85 | Missed -8.0% |
| Q3 '25 | $1.86 | $2.25 | Beat +21.0% |
| Q2 '25 | $1.43 | $1.47 | Beat +2.8% |
| Q1 '25 | $1.45 | $1.49 | Beat +2.8% |
Collegium Pharmaceutical Quarterly Financial Trends
| Metric | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 159M | 182M | 178M | 188M | 209M | 205M | 194M | 200M |
| Gross margin | 60.8% | 54.0% | 54.8% | 57.7% | 61.7% | 62.5% | 60.6% | 55.2% |
| Operating margin | 21.9% | 20.9% | 12.2% | 18.7% | 30.4% | 28.8% | 16.5% | 1.9% |
| Net income | 9.3M | 13M | 2.4M | 12M | 32M | 17M | 14M | -15M |
| Net margin | 5.9% | 6.9% | 1.4% | 6.4% | 15.0% | 8.3% | 7.5% | -7.5% |
| EPS | $1.61 | $1.77 | $1.49 | $1.47 | $2.25 | $1.85 | $1.76 | $1.57 |
Collegium Pharmaceutical Earnings Trend Analysis
Over the eight quarters from Q3 '24 to Q2 '26, Collegium Pharmaceutical’s quarterly revenue moved from $159M to $200M. Net margin compressed from 5.9% to -7.5%, against a 55.2% gross margin in the most recent quarter — a read on whether revenue growth is translating into profit. Collegium Pharmaceutical has beaten Wall Street EPS estimates in 7 of its last 8 reported quarters.
When Is Collegium Pharmaceutical’s Next Earnings Date?
Collegium Pharmaceutical reports earnings on a quarterly schedule. Its most recent report covered Q2 '26. For the confirmed upcoming date — and every other company reporting soon — see the COLL earnings calendar.
Frequently Asked Questions: Collegium Pharmaceutical Earnings
Collegium Pharmaceutical's next earnings date has not been confirmed yet. See the earnings calendar for all upcoming reports.
Collegium Pharmaceutical reported Q2 '26 EPS of $1.57 on revenue of $200M (+6.3% YoY). Collegium Pharmaceutical beat estimates, reporting $1.57 vs. the $1.48 estimate.
Collegium Pharmaceutical reported Q2 '26 revenue of $200M, up 6.3% from the same quarter a year earlier.
Signals like job postings, web traffic, and employee sentiment reflect business activity in real time and can move before quarterly results are reported. AltIndex combines them with 25+ others in the COLL AI Score.
